论文部分内容阅读
对60例重度窒息儿进行苯巴比妥预防颅内病变及惊厥的对照研究。苯巴比妥组接受负荷量平均 年龄为生后5.6小时,其生后第四天的血清药物浓度为21.9±5.9μg/ml,颅内病变发生率为53.3％;对照组的颅内病变发生率为83.3％,两组之间的差异有显著性意义(x~2=6.239,P<0.05)。苯巴比妥组在给药以后,无1例发生惊厥,对照组的惊厥持续时间则显著延长(t=3.068,P<0.05)。研究显示苯巴比妥可显著降低窒息后颅内病变发生率,并有效预防和控制了窒息后惊厥的发生。建设对重度窒息儿宜在生后早期应用苯巴比妥预防,以降低颅内病变及惊厥的发生率。
60 cases of severe asphyxia children phenobarbital intracranial lesions and convulsions control study. The average load of phenobarbital group 5.6 hours after birth, the fourth day after birth serum drug concentration was 21.9 ± 5.9μg / ml, the incidence of intracranial lesions was 53.3%; intracranial lesions occurred in the control group The rate was 83.3%. The difference between the two groups was significant (x ~ 2 = 6.239, P <0.05). In the phenobarbital group, no convulsion occurred in one patient after the administration, and the duration of convulsion in the control group was significantly prolonged (t = 3.068, P <0.05). Studies have shown that phenobarbital can significantly reduce the incidence of intracranial lesions after asphyxia and effectively prevent and control the occurrence of convulsions after asphyxia. Construction of severe asphyxia should be appropriate in the early postpartum phenobarbital prophylaxis to reduce the incidence of intracranial lesions and convulsions.